Establishment of shared antigen reactive cytotoxic T lymphocyte using co-stimulatory molecule introduced autologous...

Area of Science:

• Immunology
• Oncology
• Cellular Biology

Background:

• Cytotoxic T lymphocytes (CTLs) are crucial for tumor rejection.
• Previous identification of tumor-associated antigens (TAAs) has primarily focused on melanoma, with limited success in clinical trials.
• There is a need for more immunogenic TAAs and effective strategies to overcome immune tolerance.

Purpose of the Study:

• To establish a human leukocyte antigen (HLA)-A24-restricted CTL line from a lung cancer patient.
• To investigate the role of B7.1 (CD80) in overcoming immunological tolerance.
• To develop a tool for identifying widely shared, HLA-A24-restricted TAAs.

Main Methods:

• Established an HLA-A24-restricted CTL line (TcLHK2 line1) from a lung cancer patient's pleural effusion.
• Utilized autologous lung cancer cells engineered to express B7.1 (CD80) as antigen-presenting cells (APCs).
• Assessed the recognition capabilities of the CTL line against autologous and allogeneic cancer cell lines.

Main Results:

• Successfully established the TcLHK2 line1, an HLA-A24-restricted CTL line.
• TcLHK2 line1 recognized autologous lung adenocarcinoma cells (LHK2) in an HLA-A24-restricted manner.
• The CTL line also recognized allogeneic lung adenocarcinoma, gastric carcinoma, and melanoma cell lines expressing HLA-A24.

Conclusions:

• The co-stimulatory molecule B7.1 (CD80) may play a significant role in overcoming immunological tolerance.
• The TcLHK2 line1 is a valuable tool for identifying shared TAAs restricted by HLA-A24.
• Further analysis holds promise for discovering novel TAAs and advancing cancer immunotherapy.